1. Home
  2. CDP vs CRNX Comparison

CDP vs CRNX Comparison

Compare CDP & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo COPT Defense Properties of Beneficial Interest

CDP

COPT Defense Properties of Beneficial Interest

HOLD

Current Price

$34.46

Market Cap

3.6B

Sector

Real Estate

ML Signal

HOLD

Logo Crinetics Pharmaceuticals Inc.

CRNX

Crinetics Pharmaceuticals Inc.

HOLD

Current Price

$34.70

Market Cap

3.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CDP
CRNX
Founded
1988
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.6B
3.9B
IPO Year
1996
2018

Fundamental Metrics

Financial Performance
Metric
CDP
CRNX
Price
$34.46
$34.70
Analyst Decision
Buy
Strong Buy
Analyst Count
7
8
Target Price
$34.57
$76.75
AVG Volume (30 Days)
840.9K
884.6K
Earning Date
04-27-2026
05-07-2026
Dividend Yield
4.14%
N/A
EPS Growth
8.94
N/A
EPS
0.34
N/A
Revenue
$763,923,000.00
$1,039,000.00
Revenue This Year
$1.18
$720.10
Revenue Next Year
$3.71
$184.67
P/E Ratio
$100.88
N/A
Revenue Growth
1.41
N/A
52 Week Low
$26.91
$25.83
52 Week High
$34.78
$57.99

Technical Indicators

Market Signals
Indicator
CDP
CRNX
Relative Strength Index (RSI) 73.02 47.34
Support Level $30.86 $33.15
Resistance Level N/A $37.23
Average True Range (ATR) 0.74 1.42
MACD 0.27 0.07
Stochastic Oscillator 89.74 52.19

Price Performance

Historical Comparison
CDP
CRNX

About CDP COPT Defense Properties of Beneficial Interest

COPT Defense Properties is a fully-integrated and self-managed real estate investment trust (REIT) focused on owning, operating and developing properties in locations proximate to, or sometimes containing, key U.S. Government (USG) defense installations and missions. Its tenants include the USG and their defense contractors, who are engaged in priority national security activities, and who generally require mission-critical and high security property enhancements. Its properties include 195 operating properties totaling approximately 22.4 million square feet comprised of 16.5 million square feet in 164 office properties and 5.9 million square feet in 31 single-tenant data center shells.

About CRNX Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.

Share on Social Networks: